Lots of FDA approval updates to discuss from the past few weeks:
-Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metastatic NSLCLC
-Encorafenib approval with cetuximab + FOLFOX
-Teclistamab + Daratumumab approved in 2nd line setting for r/r multiple myeloma
-Acalabrutinib + venetoclax (but NOT acalabrutinib + venetoclax + obinutuzumab) is approved for CLL
Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm
